MovDisordV3, PubMed, Curation, bibRecord, 003930

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).

Identifieur interne : 003930 ( PubMed/Curation ); précédent : 003929; suivant : 003931

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).

Auteurs : Brad A. Racette [États-Unis] ; Mikula Stambuk ; Joel S. Perlmutter

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.

RBID : pubmed:12360571

English descriptors

KwdEn :
- Blepharospasm (drug therapy), Blinking (drug effects), Botulinum Toxins, Type A (pharmacology), Botulinum Toxins, Type A (therapeutic use), Female, Humans, Middle Aged, Treatment Outcome.
MESH :
- chemical , pharmacology : Botulinum Toxins, Type A.
- drug effects : Blinking.
- drug therapy : Blepharospasm.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- Female, Humans, Middle Aged, Treatment Outcome.

Abstract

We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.

DOI: 10.1002/mds.10209
PubMed: 12360571

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003930

Links to Exploration step

pubmed:12360571

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12360571</idno>
<idno type="pmid">12360571</idno>
<idno type="doi">10.1002/mds.10209</idno>
<idno type="wicri:Area/PubMed/Corpus">003930</idno>
<idno type="wicri:Area/PubMed/Curation">003930</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm (drug therapy)</term>
<term>Blinking (drug effects)</term>
<term>Botulinum Toxins, Type A (pharmacology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12360571</PMID>
<DateCreated><Year>2002</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>01</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>5</Issue>
<PubDate><Year>2002</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</ArticleTitle>
<Pagination><MedlinePgn>1098-100</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</AbstractText>
<CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Racette</LastName>
<ForeName>Brad A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stambuk</LastName>
<ForeName>Mikula</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Perlmutter</LastName>
<ForeName>Joel S</ForeName>
<Initials>JS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS31001</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001764">Blepharospasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001767">Blinking</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>1</Month>
<Day>9</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12360571</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10209</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003930 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003930 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:12360571
   |texte=   Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:12360571" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki